TY  - JOUR
AU  - Afshar-Oromieh, Ali
AU  - Debus, Nils
AU  - Uhrig, Monika
AU  - Hope, Thomas A
AU  - Evans, Michael J
AU  - Holland-Letz, Tim
AU  - Giesel, Frederik L
AU  - Kopka, Klaus
AU  - Hadaschik, Boris
AU  - Kratochwil, Clemens
AU  - Haberkorn, Uwe
TI  - Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.060
JO  - European journal of nuclear medicine and molecular imaging
VL  - 45
IS  - 12
SN  - 1619-7089
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - DKFZ-2018-01698
SP  - 2045 - 2054
PY  - 2018
AB  - Since the introduction of PSMA PET/CT with 68Ga-PSMA-11, this modality for imaging prostate cancer (PC) has spread worldwide. Preclinical studies have demonstrated that short-term androgen deprivation therapy (ADT) can significantly increase PSMA expression on PC cells. Additionally, retrospective clinical data in large patient cohorts suggest a positive association between ongoing ADT and a pathological PSMA PET/CT scan. The present evaluation was conducted to further analyse the influence of long-term ADT on PSMA PET/CT findings.A retrospective analysis was performed of all 1,704 patients who underwent a 68Ga-PSMA-11 PET/CT scan at our institution from 2011 to 2017 to detect PC. Of 306 patients scanned at least twice, 10 had started and continued ADT with a continuous clinical response between the two PSMA PET/CT scans. These ten patients were included in the current analysis which compared the tracer uptake intensity and volume of PC lesions on PSMA PET/CT before and during ongoing ADT.Overall, 31 PC lesions were visible in all ten patients before initiation of ADT. However, during ongoing ADT (duration 42-369 days, median 230 days), only 14 lesions were visible in eight of the ten patients. The average tracer uptake values decreased in 71
LB  - PUB:(DE-HGF)16
C6  - pmid:29980832
C2  - pmc:PMC6182397
DO  - DOI:10.1007/s00259-018-4079-z
UR  - https://inrepo02.dkfz.de/record/141171
ER  -